TriSalus Life Sciences is an immunotherapy company on a mission to extend and improve the lives of patients living with liver and pancreatic tumors. TriSalus' organ-specific platform integrates novel therapeutics and innovative drug delivery technology to address the dual challenges of immune response suppression and ineffective drug delivery due to high intratumoral pressure, two of the most significant barriers that limit the effectiveness of therapeutics for liver and pancreatic tumors.
Location: United States, Colorado, Westminster
Employees: 51-200
Total raised: $50M
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Tullis Hea... | tullisfund... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.04.2024 | - | $50M | OrbiMed |
Mentions in press and media 18
| Date | Title | Description |
| 30.04.2024 | TriSalus Life Sciences Secures up to $50 Million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives | DENVER–(BUSINESS WIRE)–Apr. 30, 2024– TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced the closing of a debt financing facility for up to $50 million with OrbiMed, a healthcare investment firm. The capital is expected to provide... |
| 29.02.2024 | TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors | Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, treatment refractory, and higher disease burde... |
| 20.11.2022 | TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies | Data further substantiates potential to significantly improve immunotherapy outcomes for patients with liver and pancreatic tumors |
| 14.11.2022 | TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation | TriSalus Life Sciences , a privately held oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors, announced it has entere... |
| 14.11.2022 | TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation | Oncology Therapeutics Company Focused on Transforming Cancer Treatment with Proprietary Innovative Therapies and Disruptive Delivery Technology |
| 10.05.2022 | TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial | Studying the delivery of SD-101 via pressure-enabled drug delivery in adults with hepatocellular carcinoma or intrahepatic cholangiocarcinoma |
| 10.02.2022 | TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisory Boards | Additions will support company focus to overcome liver and pancreatic cancer treatment barriers and enable more patients to benefit from immunotherapy |
| 20.01.2022 | TriSalus Life Sciences Announces Collaboration with the University of Colorado Anschutz Medical Campus | Three-year program aims to advance research on innovative immuno-oncology treatments for patients with liver and pancreatic tumors |
| 06.01.2022 | Global Liver Institute and TriSalus Life Sciences Launch New Liver Cancer Resource Hub | “Liver Central” is a comprehensive online guide for liver cancer researchers, clinicians and patients |
| 14.04.2021 | TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists | DENVER, and CHICAGO, APRIL 14, 2021 –TriSalus Life Sciences®, an emerging immuno-oncology company committed to transforming outcomes for patients with liver and pancreatic tumors, today announced data presented at the American Association o... |
Show more